Staphylococcal protein A (SpA) is a key virulence factor that enables Staphylococcus aureus to evade host innate and adaptive immune responses. The immunomodulatory properties of SpA have led to a hypothesis that it may have pharmacological applications as a treatment for autoimmune disease. Clinical trials are underway to test whether ultrapure SpA can be used to treat immune thrombocytopenia and rheumatoid arthritis. Here, we examine the potential of SpA as an innovative drug to manage autoimmune movement disorders.
Gemma Eftimiadi, Piergiuseppe Vinai and Costantino Eftimiadi*
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : April 18, 2019